Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07117474
PHASE1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-12-24

Completion Date

2025-12

Last Updated

2025-08-12

Healthy Volunteers

Yes

Interventions

DRUG

HRS-9563, placebo

A single subcutaneous injection of HRS-9563 injection or placebo was administered

Locations (1)

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China